Ferring Holding SA alleges that a generic version of Firmagon proposed by Jiangsu Hansoh Pharmaceutical Group Co. infringes six patents for the cancer treatment, including one licensed from PolyPeptide Group AG, a federal lawsuit in Delaware says.
Firmagon is an injection used to treat advanced prostate cancer. The US Food and Drug Administration approved the drug in December 2008, according to a complaint filed Wednesday in the US District Court for the District of Delaware.
Ferring Pharmaceuticals Inc., Ferring International Center SA, and Ferring BV—subsidiaries of Switzerland-based Ferring—filed the suit with co-plaintiff Polypeptide Laboratories A/S, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.